14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $1.0B | -$205M | 53.8% | -18.5% | -131.9% | -23.2% | -$30M | $310M | $91M |
| 2024 | $940M | -$96M | 52.1% | -10.5% | -36.5% | -9.9% | $5M | $349M | $69M |
| 2023 | $748M | -$223M | 49.2% | -31.2% | -71.0% | -23.4% | -$59M | $285M | $59M |
| 2022 | $801M | -$95M | 51.5% | -11.6% | -21.5% | -9.0% | $16M | — | $173M |
| 2021 | $703M | $16M | 53.5% | 3.2% | 3.6% | 1.7% | $97M | — | $71M |
| 2020 | $499M | -$34M | 52.2% | -1.6% | -9.4% | -4.8% | -$3M | — | $95M |
| 2019 | $362M | -$25M | 53.6% | -4.6% | -12.7% | -7.6% | $22M | — | $51M |
| 2018 | $184M | -$123M | 48.9% | -24.3% | -93.4% | -59.4% | -$11M | — | $42M |
| 2017 | $108M | -$73M | 41.0% | -58.5% | 250.6% | -76.6% | -$72M | $83M | $14M |
| 2016 | $84M | -$83M | 28.0% | -92.6% | 1407.9% | -74.2% | -$70M | $81M | $45M |
| 2015 | — | -$72M | — | — | -114.1% | -58.1% | — | $30M | $43M |
| 2014 | — | -$80M | — | — | -145.7% | -74.7% | — | $30M | $31M |
| 2013 | — | -$63M | — | — | -54.6% | -38.9% | — | — | $124M |
| 2012 | — | -$33M | — | — | 31.1% | — | — | — | $17M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $255M | -$21M | 56.9% | -5.4% | -16.2% | -1.8% | -$39M | $603M | $63M |
| Mar '26 | $247M | -$20M | 55.3% | -7.1% | -15.4% | -1.8% | $5M | $602M | $179M |
| Dec '25 | $290M | -$589000 | 57.7% | 2.9% | -0.4% | -0.1% | $3M | $310M | $91M |
| Sep '25 | $249M | -$21M | 53.9% | -9.2% | -15.9% | -2.4% | $4M | $310M | $92M |
| Jun '25 | $241M | -$52M | 52.3% | -21.5% | -39.3% | -6.0% | -$16M | $309M | $64M |
| Mar '25 | $234M | -$131M | 50.5% | -51.6% | -84.1% | -14.2% | -$21M | $309M | $54M |
| Dec '24 | $283M | $755000 | 55.7% | -0.2% | 0.3% | 0.1% | $8M | $349M | $69M |
| Sep '24 | $244M | -$23M | 51.1% | -10.7% | -9.8% | -2.4% | $22M | $348M | $49M |
| Jun '24 | $222M | -$31M | 50.8% | -13.9% | -13.2% | -3.3% | -$12M | $348M | $48M |
| Mar '24 | $192M | -$43M | 49.4% | -21.7% | -17.6% | -4.5% | -$12M | — | $59M |
| Dec '23 | $197M | -$30M | 47.4% | -17.8% | -9.6% | -3.1% | -$12M | $285M | $59M |
| Sep '23 | $186M | -$33M | 48.4% | -17.0% | -10.5% | -3.5% | -$5M | — | $80M |
| Jun '23 | $196M | -$36M | 51.9% | -19.8% | -10.9% | -3.8% | -$14M | — | $131M |
| Mar '23 | $169M | -$124M | 48.9% | -75.5% | -36.6% | -13.0% | -$27M | — | $128M |
| Dec '22 | $221M | -$16M | 52.4% | -8.1% | -3.6% | -1.5% | $193000 | — | $173M |
| Sep '22 | $205M | -$49M | 51.1% | -23.2% | -11.6% | -4.7% | $10M | — | $124M |
| Jun '22 | $200M | -$15M | 50.9% | -6.1% | -3.3% | -1.5% | -$5M | — | $115M |
| Mar '22 | $176M | -$15M | 51.8% | -8.7% | -3.4% | -1.4% | $11M | — | $94M |
| Dec '21 | $210M | $11M | 54.2% | 6.1% | 2.5% | 1.2% | $14M | — | $71M |
| Sep '21 | $180M | $6M | 53.9% | 4.3% | 1.5% | 0.7% | $31M | — | $112M |
How the market has priced TNDM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Tandem Diabetes Care Inc's revenue has grown 15.3% per year. These are computed facts, not advice.
As of FY2025, Tandem Diabetes Care Inc reported $310M of total debt against $91M of cash; operating income covered interest expense -23.7×.
In FY2025, gross margin was 53.8%, operating margin -18.5%, and net margin -20.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.